Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral

Core Viewpoint - Geron Corporation (NASDAQ:GERN) is undergoing a strategic restructuring plan aimed at long-term value creation and improved financial discipline, while maintaining a Neutral rating from H.C. Wainwright [1][3]. Group 1: Strategic Restructuring - The strategic restructuring plan will reduce Geron's workforce by approximately one-third, from around 260 employees [2]. - This restructuring is intended to streamline operations and focus on the commercial growth of RYTELO in the US, as well as explore international opportunities and progress on the Phase 3 IMpactMF trial [2][4]. Group 2: Financial Outlook - Geron expects its operating expenses in 2026 to be lower than those in 2025, with most cuts completed by the first quarter of 2026 [3]. - The company is projected to reach profitability in the second half of 2026 based on the anticipated reduction in operating expenses [3]. Group 3: Future Developments - An update on Geron's European commercialization strategy is expected in the first half of 2026 [4]. - Interim overall survival data from the IMpactMF trial is anticipated to be shared in the second half of 2026 [4].